Literature DB >> 16018155

HIV-related neurological syndromes reduce health-related quality of life.

Rupang Pandya1, Hartmut B Krentz, M John Gill, Christopher Power.   

Abstract

BACKGROUND: Human immunodeficiency virus (HIV) infection frequently results in neurological complications but the impact of different neurological syndromes on patients' quality of life remains unknown.
METHODS: We investigated health-related quality of life (HRQoL) parameters among HIV/Acquired Immune Deficiency Syndrome (AIDS) patients with and without neurological disease, including 11 dimensions of HRQoL within the Medical Outcomes Short-form Health Survey-HIV.
RESULTS: Comparisons of sociodemographic and systemic clinical variables did not differ between HIV/AIDS patients with (n=94) and without (n=75) neurological disease. However, patients with neurological diseases exhibited significantly lower HRQoL scores compared to matched controls, which was most evident among HIV/AIDS patients with cognitive impairment and sensory neuropathy. Prospective analysis revealed diminishing HRQoL scores prior to neurological diagnosis followed by a progressive and sustained improvement in HRQoL scores after intervention over a 96-week period.
CONCLUSIONS: These studies indicate that while HIV-related neurological diseases are associated with reduced HRQoL scores, enhanced neurological care has a positive impact on HIV/AIDS patients' overall well-being.

Entities:  

Mesh:

Year:  2005        PMID: 16018155     DOI: 10.1017/s0317167100003978

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  20 in total

1.  Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy.

Authors:  Asha R Kallianpur; Todd Hulgan
Journal:  Pharmacogenomics       Date:  2009-04       Impact factor: 2.533

2.  NeuroAIDS: a watershed for mental health and nervous system disorders.

Authors:  Jennifer A McCombe; Farshid Noorbakhsh; Craig Buchholz; Michael Trew; Christopher Power
Journal:  J Psychiatry Neurosci       Date:  2009-03       Impact factor: 6.186

3.  Dissociable Contributions of Precuneus and Cerebellum to Subjective and Objective Neuropathy in HIV.

Authors:  Natalie M Zahr; Kilian M Pohl; Adolf Pfefferbaum; Edith V Sullivan
Journal:  J Neuroimmune Pharmacol       Date:  2019-02-11       Impact factor: 4.147

4.  Prevalence and Risk Factors of HIV-Associated Neurocognitive Disorders in Rural Southwestern Uganda.

Authors:  Jane Kasozi Namagga; Godfrey Zari Rukundo; Joachim G Voss
Journal:  J Assoc Nurses AIDS Care       Date:  2019 Sep-Oct       Impact factor: 1.354

5.  Incident neuropathy in HIV-infected patients on HAART.

Authors:  Beau K Nakamoto; Aaron McMurtray; James Davis; Victor Valcour; Michael R Watters; Bruce Shiramizu; Dominic C Chow; Kalpana Kallianpur; Cecilia M Shikuma
Journal:  AIDS Res Hum Retroviruses       Date:  2010-07       Impact factor: 2.205

Review 6.  Delineating HIV-associated neurocognitive disorders using transgenic models: the neuropathogenic actions of Vpr.

Authors:  Christopher Power; Elizabeth Hui; Pornpun Vivithanaporn; Shaona Acharjee; Maria Polyak
Journal:  J Neuroimmune Pharmacol       Date:  2011-09-15       Impact factor: 4.147

Review 7.  Update of HIV-Associated Sensory Neuropathies.

Authors:  Angela Aziz-Donnelly; Taylor B Harrison
Journal:  Curr Treat Options Neurol       Date:  2017-08-31       Impact factor: 3.598

Review 8.  The effects of cocaine on HIV transcription.

Authors:  Mudit Tyagi; Jaime Weber; Michael Bukrinsky; Gary L Simon
Journal:  J Neurovirol       Date:  2015-11-16       Impact factor: 2.643

9.  Contribution of CNS cells in NeuroAIDS.

Authors:  Ashish Swarup Verma; Udai Pratap Singh; Premendra Dhar Dwivedi; Anchal Singh
Journal:  J Pharm Bioallied Sci       Date:  2010-10

10.  Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies.

Authors:  Taylor Harrison; Sachiko Miyahara; Anthony Lee; Scott Evans; Barbara Bastow; David Simpson; Ian Gilron; Robert Dworkin; Eric S Daar; Linda Wieclaw; David B Clifford
Journal:  Pain Med       Date:  2013-04-08       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.